# Qing Zhou

Source: https://onco.cc/people/qing-zhou/  
OnCo record `qing-zhou` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chinese thoracic oncologist behind HARMONi-2, where the PD-1/VEGF bispecific ivonescimab beat pembrolizumab head to head.

## Summary

Qing Zhou led HARMONi-2, the first randomised trial in which a new agent (ivonescimab, a PD-1 and VEGF bispecific antibody) beat pembrolizumab on progression-free survival in PD-L1-positive NSCLC, and HARMONi-A in EGFR-mutant disease after TKI failure. She works alongside Yi-Long Wu at the Guangdong Lung Cancer Institute and leads CTONG trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; bispecific; china
- Role: Chief of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
- Specialisms: EGFR-mutant lung cancer; Bispecific antibodies; Immunotherapy; Chinese lung cancer trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Zhou%20Q%5BAuthor%5D%20ivonescimab

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Guangdong Provincial People's Hospital](https://onco.cc/institutions/guangdong-provincial-peoples-hospital/)
- trials: [HARMONi-2](https://onco.cc/trials/harmoni-2/)
- key papers: [HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-harmoni-2-lancet-2025/)

---
JSON: https://onco.cc/api/v1/entities/qing-zhou.json